הכנסות שנתיות של החברה Purple Biotech Ltd (PPBT)

Purple Biotech management is focusing on developing methods to combat tumor resistance, which is confirmed by the company's trading revenue trend on the GURU.Markets chart, where 0.00 serves as the base parameter value. The development of the CM24 antibody creates a closed patent perimeter, while intensive trials of CM24 and NT219 drugs for solid tumors ensure high scientific productivity.

Purple Biotech operates as a fabless biotech, fully outsourcing antibody production and clinical trials to external contractors. The company's sales statistics record actual cash inflows from realizations, allowing investors to filter out speculative noise and assess real demand for drugs, where any sharp impulse in the curve serves as an indicator of either fundamental growth or market overheating.